IRIS
LODI, Tiziana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.709
AS - Asia 6.224
EU - Europa 4.652
SA - Sud America 889
AF - Africa 281
Continente sconosciuto - Info sul continente non disponibili 247
OC - Oceania 5
Totale 21.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.455
SG - Singapore 2.335
CN - Cina 1.810
VN - Vietnam 951
IT - Italia 830
IE - Irlanda 813
SE - Svezia 685
BR - Brasile 676
FI - Finlandia 557
UA - Ucraina 491
HK - Hong Kong 471
DE - Germania 422
FR - Francia 223
ZA - Sudafrica 210
NL - Olanda 193
GB - Regno Unito 165
CA - Canada 152
TR - Turchia 147
BD - Bangladesh 135
RU - Federazione Russa 87
IN - India 67
AR - Argentina 55
IQ - Iraq 45
CO - Colombia 41
EC - Ecuador 40
JP - Giappone 39
MX - Messico 38
BE - Belgio 36
ES - Italia 31
KR - Corea 27
PH - Filippine 23
VE - Venezuela 23
PL - Polonia 21
ID - Indonesia 19
UZ - Uzbekistan 19
PK - Pakistan 18
CL - Cile 16
JM - Giamaica 16
PY - Paraguay 14
TH - Thailandia 14
CR - Costa Rica 12
CZ - Repubblica Ceca 12
EG - Egitto 12
SA - Arabia Saudita 12
CI - Costa d'Avorio 11
UY - Uruguay 11
MA - Marocco 10
TW - Taiwan 10
AE - Emirati Arabi Uniti 9
DO - Repubblica Dominicana 9
KZ - Kazakistan 9
PE - Perù 9
AT - Austria 8
IL - Israele 8
PT - Portogallo 8
RS - Serbia 8
DZ - Algeria 7
EU - Europa 7
IR - Iran 7
KE - Kenya 7
LT - Lituania 7
AL - Albania 6
NP - Nepal 6
TN - Tunisia 6
AZ - Azerbaigian 5
DK - Danimarca 5
JO - Giordania 5
MK - Macedonia 5
NO - Norvegia 5
BG - Bulgaria 4
CH - Svizzera 4
EE - Estonia 4
HN - Honduras 4
KG - Kirghizistan 4
LB - Libano 4
NI - Nicaragua 4
OM - Oman 4
RO - Romania 4
SC - Seychelles 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
GP - Guadalupe 3
GT - Guatemala 3
MD - Moldavia 3
MY - Malesia 3
NG - Nigeria 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
ET - Etiopia 2
GE - Georgia 2
GY - Guiana 2
KH - Cambogia 2
LV - Lettonia 2
Totale 20.739
Salva come PNG Salva come JPEG
Città #
Singapore 1.113
Ashburn 994
Dublin 802
Chandler 791
San Jose 731
Santa Clara 675
Jacksonville 542
Hong Kong 442
Beijing 418
Dallas 367
Council Bluffs 298
Ann Arbor 282
Dearborn 282
Ho Chi Minh City 279
Boardman 237
Hanoi 210
Nanjing 209
Parma 208
Johannesburg 193
Los Angeles 177
Princeton 155
Lauterbourg 137
San Mateo 132
New York 130
Izmir 123
Wilmington 119
Shanghai 111
Toronto 92
Jinan 75
Shenyang 71
São Paulo 71
Hefei 61
Nanchang 61
Helsinki 59
Des Moines 55
Moscow 53
Kunming 52
Munich 51
Buffalo 50
Woodbridge 50
Hebei 48
Haiphong 43
Washington 41
Da Nang 39
Guangzhou 38
Phoenix 37
Brussels 34
Tianjin 33
The Dalles 31
Falls Church 30
Jiaxing 30
Columbus 29
Atlanta 28
Brooklyn 28
Houston 28
Tokyo 27
Changsha 26
Dosolo 26
Seattle 25
Milan 24
Rio de Janeiro 22
Rome 22
Orem 21
Baghdad 20
Zhengzhou 20
Amsterdam 19
Frankfurt am Main 19
Redmond 18
Warsaw 18
Chicago 17
Padova 17
Bremen 16
Can Tho 16
Denver 16
Haikou 16
London 16
Marseille 16
Quito 16
Tashkent 16
Bologna 15
Catania 15
Hangzhou 15
Belo Horizonte 14
Biên Hòa 14
Chennai 14
Fremont 14
Fuzhou 14
Montreal 14
North Bergen 14
Bogotá 13
Hải Dương 13
Modena 13
San Francisco 13
Seoul 13
Taizhou 13
Brasília 12
Guayaquil 12
Nuremberg 12
Abidjan 11
Kingston 11
Totale 12.223
Salva come PNG Salva come JPEG
Nome #
Mechanistic insights on the mode of action of an antiproliferative thiosemicarbazone-nickel complex revealed by an integrated chemogenomic profiling study 349
Yeast, worm, patient’s fibroblasts and zebrafish as models for drug repositioning of molecules targeting POLG-related diseases 248
A yeast-based repurposing approach revealed modulation of dNTP pool as a therapeutic target to treat mitochondrial DNA depletion syndromes 230
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 211
DNA polymerase [gamma] and disease: what we have learned from yeast 208
A chemical genomic approach to characterize the antiproliferative activity of metal based drugsdriven by phenotypic screening in yeast as a model organism 208
Screening of thiosemicarbazones as antimycotic drugs 206
A chemical genomic approach to characterize the antiproliferative activity of metal-based drugs driven by phenotipic screening in yeast as a model organism 205
Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island 203
Sabotage at the powerhouse? Unraveling the Molecular Target of 2-Isopropylbenzaldehyde Thiosemicarbazone, a Specific Inhibitor of Aflatoxin Biosynthesis and Sclerotia Development in Aspergillus flavus, Using Yeast as a Model System 199
Characterization of a promoter mutation in the CYP3 gene of S. cerevisiae which cancels regulation by Cyp1p (Hap1p) without affecting its binding site 198
Amino and carboxy-terminal extensions of yeast mitochondrial DNA polymerase assemble both the polymerization and exonuclease active sites 192
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 189
A Klaac null mutant of Kluyveromyces lactis is complemented by a single copy of the Saccharomyces cerevisiae AAC1 gene 186
Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models 185
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 184
A single nucleotide polymorphism in the DNA polymerase gamma gene of Saccharomyces cerevisiae laboratory strains is responsible for increased mitochondrial DNA mutability 182
Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy 182
A yeast-based repurposing approach for the treatment of mitochondrial DNA depletion syndromes led to the identification of molecules able to modulate the dNTP pool 180
The Power of Yeast in Modelling Human Nuclear Mutations Associated with Mitochondrial Diseases 178
Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations 178
IMP2, a nuclear gene controlling the mitochondrial dependence of galactose, maltose and raffinose utilization in Saccharomyces cerevisiae. 176
Investigation of mupirocin susceptibility in bifidobacteria: physiological and genetic insights. 175
A steric gate prevents mutagenic dATP incorporation opposite 8-oxo-deoxyguanosine in mitochondrial DNA polymerases 174
In vitro evaluation of the activity of thiosemicarbazone derivatives against mycotoxigenic fungi affecting cereals 174
Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of Clofilium tosylate as a potential therapeutic chemical against POLG-related diseases 173
Behaviour of Saccharomyces cerevisiae wine strains during adaptation to unfavourable conditions of fermentation on synthetic medium: Cell lipid composition, membrane integrity, viability and fermentative activity 171
S. cerevisiae carrying a MGM1/OPA1 chimeric gene: a model for the study of dominant optic atrophy and for drug discovery 169
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 168
Efficient clofilium tosylate-mediated rescue of POLG-related disease phenotypes in zebrafish 168
Allelism of IMP1 and GAL2 genes of Saccharomyces cerevisiae 167
The identification of beneficial molecules for mitochondrial diseases: Saccharomyces cerevisiae as powerful model 167
Yeast as a model of mitochondrial dysfunctions: neurodegenerative diseases and cancer. 164
Carbon catabolite repression in Kluyveromyces lactis: isolation and characterization of the KlDLD gene encoding the mitochondrial enzyme D-lactate ferricytochrome c oxidoreductase. 164
Genetic and chemical rescue of the Saccharomyces cerevisiae phenotype induced by mitochondrial DNA polymerase mutations associated with progressive externalophthalmoplegia in humans 162
The mitochondrial disulfide relay system protein GFER is mutated in autosomal-recessive myopathy with cataract and combined respiratory-chain deficiency. 162
Zebrafish polg2 knock-out recapitulates human POLG-disorders; implications for drug treatment 160
Secretion of human serum albumin from Kluyveromyces lactis over-expressing KlPDI1 and KlERO1 genes 160
Antimycin- and hydroxamate-insensitive respiration in yeast 160
DEFECTIVE MITOCHONDRIAL rRNA METHYLTRANSFERASE (MRM2) CAUSES A MELAS-LIKE SYNDROME 160
A yeast-based screening unravels potential therapeutic molecules for mitochondrial diseases associated with dominant ant1 mutations 160
Cloning and characterization of the lactate-specific inducible gene KlCYB2, encoding the cytochrome b2 of Kluyveromyces lactis 159
A variable neurodegenerative phenotype with polymerase gamma mutation 158
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 158
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of DNA polymerase gamma allelic variants 157
Yeast expression of mammalian Onzin and fungal FCR1 suggests ancestral functions of PLAC8 proteins in mitochondrial metabolism and DNA repair 157
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 156
Chiral Aminoacid Containing Acyclic Ligands. I. Syntheses and Conformations 155
Overexpression of DNA Polymerase Zeta Reduces the Mitochondrial Mutability Caused by Pathological Mutations in DNA Polymerase Gamma in Yeast 155
Catabolite repression by galactose in overexpressed GAL4 strains of Saccharomyces cerevisiae 154
Dominance of yeast aac2R96H and aac2R252G mutations, equivalent to pathological mutations in ant1, is due to gain of function 154
Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein 152
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 151
Identification of drugs for the treatment of POLG-related diseases by means of a high throughput drug repurposing approach performed in Saccharomyces cerevisiae 150
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 149
A mitochondrial role in pseudohyphal constitutive mutants obtained from a natural Saccharomyces cerevisiae strain 148
Carboxylic acids permeases in yeast: two genes in Kluyveromyces lactis.” 146
Polymorphisms in DNA polymerase γ affect the mtDNA stability and the NRTI-induced mitochondrial toxicity in Saccharomyces cerevisiae 146
Characterization of KlGUT2, a gene of the glycerol-3-phosphate shuttle, in Kluyveromyces lactis 144
Saccharomyces cerevisiae as a system to discover beneficial molecules for mitochondrial diseases 143
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of Polg allelic variants 141
Construction of a yeast model system for studying in vivo susceptibility to stavudine of Polg allelic variants 138
Modeling of pathogenic variants of mitochondrial DNA polymerase: insight into the replication defects and implication for human disease 138
LYS2 gene and its mutation in Kluyveromyces lactis 137
Modification of nuclear gene expression by inhibition of mitochondrial translation during sporulation in MATa/Mata diploids of Saccharomyces cerevisiae. 137
Comparative Functional Genomics of glucose repression in laboratory and wine yeasts 136
Overexpression of DNA polymerase zeta and Rev1 reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 136
Klaac null mutant in K. lactis is complemented by a single copy of S. cerevisiae “silent” gene AAC1 136
Structural modification of cuminaldehyde thiosemicarbazone increases inhibition specificity toward aflatoxin biosynthesis and sclerotia development in Aspergillus flavus 133
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 131
Overexpression of DNA polymerase zeta reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 129
Saccharomyces cerevisiae, a model system to study the effect of mtDNA polymerase mutations associated with PEO in humans. 129
“Espressione e secrezione di una Major Urinary Protein di topo nel lievito metilotrofo Pichia pastoris” 128
Pre-clinical identification of drugs targeting polg disorders by using a zebrafish/yeast trans-species approach (ZIPPY) 126
MIG1-dependent and MIG1-independent regulation of GAL gene expression in Saccharomyces cerevisiae: role of IMP2p 125
null 124
“Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein” 124
Construction and characterization of centromeric, episomal and GFP-containing vectors for Saccharomyces cerevisiae prototrophic strains 124
Klaac null mutant in Kluyveromycs lactis is complemented by a single copy of Saccharomyces cerevisiae gene AAC1 124
Yeast as a model for drug discovery: Identification of a molecule acting as potential therapeutics for POLG-related diseases 124
Oxygen is required to restore flor strain viability and lipid biosynthesis under fermentative conditions 123
Elementi regolativi implicati nel processo di repressione /derepressione da glucosio in Kluyveromyces lactis: differenze rispetto a Saccharomyces cerevisiae 122
FLO11 expression and lipid biosynthesis are required for air-liquid biofilm formation in a Saccharomyces cerevisiae flor strain 122
FOG1 and FOG2 genes, required for the transcriptional activation of glucose-repressible genes of Kluyveromyces lactis are homologous to GAL83 and SNF1 of Saccharomyces cerevisiae 121
The power of yeast in modeling human mutations leading to mitochondrial disease 121
Il lievito come modello per lo studio di patologie mitocondriali umane 120
Recurrent De Novo Dominant Mutations in SLC25A4 Cause Severe Early-Onset Mitochondrial Disease and Loss of Mitochondrial DNA Copy Number 120
Effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisiae 119
Studio degli effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisae 119
Studio del sistema ADP/ATP carrier in Kluyveromyces lactis: effetti fenotipici della distruzione del gene KlAAC e della introduzione del gene ScAAC1 nel mutante derivato. 119
Three target genes for the transcriptional activator Cat8p of Kluyveromyces lactis: acetyl coenzyme A synthetase genes KlACS1 and KlACS2 and lactate permease gene KlJEN1 119
Yeast model for drug discovery: Identification of molecules acting as potential therapeutics for POLG-related diseases 118
Mitmed: a multicenter consortium for the identification and characterization of nuclear genes responsisble for human mitochondrial disorders 117
Regulation of heat shock response in Saccharomyces cerevisiae. 116
Mutation D104G in ANT1 gene: complementation study in Saccharomyces cerevisiae as a model system 115
“MAJOR URINARY PROTEINS: STUDIES ON THE BINDING OF FLUORESCENT MOLECULES AND ITS 13C AND 15N ENRICHED EXPRESSION IN PICHIA PASTORIS” 115
Modification of nuclear gene expression by inhibition of mitochondrial translation during sporulation in Mata/Mata diploids of S. cerevisiae 115
Klaac null mutant in K.lactis is complemented by a single copy of S.cerevisiae gene AAC1 114
Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model 114
Effect of erythromycin upon proteins pattern of heat shocked S. cerevisiae. Identification of new classes of heat-shock and heat-stroke products 113
Totale 15.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.636
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022734 0 0 0 36 25 24 103 120 34 67 50 275
2022/20232.873 312 276 217 220 232 329 28 193 934 18 87 27
2023/20241.028 54 86 33 30 89 241 85 112 15 88 80 115
2024/20253.286 36 176 191 224 385 505 103 132 398 280 237 619
2025/20266.778 581 668 723 644 974 377 833 195 929 513 232 109
2026/20271.357 186 336 322 513 0 0 0 0 0 0 0 0
Totale 21.007